IXICO plc IXICO announces GBP1.9 million new study award (6936G)
27 Novembre 2020 - 8:00AM
UK Regulatory
TIDMIXI
RNS Number : 6936G
IXICO plc
27 November 2020
IXICO plc
("IXICO" or the "Company")
IXICO announces GBP1.9 million new study award
GBP1.9 million new business contract for Huntington's disease
study with existing biopharmaceutical sponsor
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience , today announces that it has executed a
contract to provide neuroimaging services that will support a phase
Ib/II clinical trial for Huntington's disease.
This will build on the Company's existing relationship with the
sponsor with whom they contracted a prior safety and efficacy trial
in 2019. By deploying innovative imaging biomarker solutions in
early phase studies, IXICO enables biopharmaceutical sponsors to
accelerate R&D decision making and maximise the value of their
drug development pipelines. The new award reflects and reinforces
the confidence customers place in IXICO as the trusted and leading
neuroimaging partner for Huntington's disease clinical trials.
This contract was included in management's expectations of
performance for the current financial year but adds to the
Company's strong order book.
Lammert Albers, Chief Commercial Officer of IXICO, commented:
"Huntington's disease is a devastating rare neurological condition
with unmet medical needs. IXICO has worked on numerous HD clinical
studies since 2007 and is pleased to build further momentum in our
mission to support our clients in delivering data analytics in
these challenging areas of rare, neurodegenerative disease. Our
services will enable clients to measure the impact of the trialled
drugs with greater confidence and potentially unlock new insights
into disease progression and drug development ."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTFLFIALDLRFII
(END) Dow Jones Newswires
November 27, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Ixico (LSE:IXI)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Ixico (LSE:IXI)
Storico
Da Apr 2023 a Apr 2024